LBA-3: Pirtobrutinib vs Bendamustine Plus Rituximab (BR) in Patients with CLL/SLL: First Results from a Randomized Phase III ...
Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® ...
Solar energy has become a visible fixture in South Africa. But many businesses are still holding off on installing solar and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback